Will trastuzumab change the optimal adjuvant systemic therapy of patients with HER2-positive breast cancer?
Santini
Daniele
D
Medical Oncology, University Campus Bio-Medico,Via Emilio Longoni, 83 00155 Rome, Italy. d.santini@ unicampus.it.
Vincenzi
Bruno
B
Tonini
Giuseppe
G